Satellos Bioscience released six-month interim adult Phase 2 data from its Trailhead study of SAT-3247, an oral AAK1 inhibitor in adults with Duchenne muscular dystrophy (DMD). In a small subset of four adults (ages 21–28) who previously completed the earlier Phase Ia/b CL-101 study, the company reported reductions in muscle fat fraction, increased total effort, stable strength, and lower creatine kinase. The company also said the safety and tolerability profile in adults was consistent with earlier findings. Satellos framed SAT-3247 as a muscle stem-cell support strategy in DMD that differs from approaches aimed at restoring dystrophin directly. The readouts come ahead of additional clinical milestones in broader populations, including potential pediatric-focused data later in development.